In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Roivant Sciences (ROIV – Research Report). The company’s ...

Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval.

Immunovant (Nasdaq: IMVT), a Roivant Sciences company, today reported top-line results from its Phase III study of batoclimab ...

Cargo was founded by two highly acclaimed cell-therapy researchers. The company raised over $500 million to develop ...

Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the ...

Immunovant (NASDAQ:IMVT) traded lower in the premarket on Wednesday after the company announced clinical trial data related ...

The companies reported Wednesday that batoclimab showed improvements in myasthenia gravis patients in a Phase 3 trial.

Roivant Sciences Ltd. CEO Matt Cline said the firm’s unit Immunovant Inc. with FcRn blocker batoclimab has established “frankly a new bar” in myasthenia gravis (MG) as the New York-based firm reported ...

State of Michigan Retirement System lessened its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV – Free Report) by 1.8% during the fourth quarter, Holdings Channel.com reports. The institutional ...

WORKFORCE CUTS. I KNOW, I KNOW, RESEARCHERS, SCIENTISTS, STUDENTS AND RAGING GRANNIES STANDING UP FOR SCIENCE AT THE CALIFORNIA STATE CAPITOL. I WAS A TEACHER, AND THIS IS A LOT ABOUT EDUCATION.

The mission of the Master of Science in Anesthesia Program is to graduate skilled and compassionate anesthetists. The admission policy reflects this goal. Applicants are considered on a variety of ...